LLY News

Recent headlines mentioning LLY, newest first.

LLY neutral

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

zacks.com·Oct 21, 2026·We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All...
LLY neutral

Sitryx to Participate in Upcoming Investor Conferences

manilatimes.net·Oct 21, 2026·Oxford, UK and Boston, MA - October 21, 2026 - Sitryx Therapeutics ("the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies...
LLY bullish

Eli Lilly (LLY) Shares Hit Record High of $1,311.21 on October 20, 2026

gurufocus.com·Oct 20, 2026·On October 20, 2026, Eli Lilly and Co (NYSE: LLY) shares surged to a new record intraday high of $1,311.21, surpassing its previous peak of $1,292.65 set in Aug...
LLY neutral

FDA Grants Orphan Drug Status to Eli Lilly's Olomorasib for Pancreatic Cancer (LLY)

gurufocus.com·Oct 5, 2026·On October 05, 2026, Eli Lilly and Co (NYSE: LLY) announced that its drug olomorasib has received orphan drug designation from the FDA for the treatment of panc...
LLY neutral

Eli Lilly's Foundayo Shows Major Diabetes Risk Reduction; LLY Stock Modestly Undervalued

gurufocus.com·Oct 1, 2026·On October 01, 2026, Eli Lilly and Co (NYSE: LLY) announced that its oral obesity treatment, Foundayo at 17.2 mg, achieved a 57% reduction in the risk of develo...
LLY neutral

Eli Lilly's Foundayo Shows Cardiovascular Benefits in Phase 3 Trial, Boosting LLY Outlook

gurufocus.com·Sep 30, 2026·On September 30, 2026, Eli Lilly and Co (NYSE: LLY) announced positive results from its Phase 3 ACHIEVE-4 trial evaluating Foundayo (orforglipron) versus insuli...
LLY neutral

Eli Lilly and Company (LLY) Presents at 2026 EASD Annual Meeting - Slideshow (NYSE:LLY) 2026-09-30

seekingalpha.com·Sep 30, 2026·To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from ...
LLY neutral

Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight

manilatimes.net·Sep 30, 2026·The coronary artery disease clinical trial analysis report delivers important insights into ongoing research of 20+ pipeline Coronary Artery Disease drugs, clin...
LLY bullish

LLY Looks 25.1% Undervalued on GF Value™ as Oral GLP-1 Gains Traction

gurufocus.com·Sep 21, 2026·On September 21, 2026, Eli Lilly and Co (NYSE: LLY) CEO Dave Ricks disclosed on CNBC that about one-third of patients starting treatment with their new GLP-1 or...
LLY neutral

They built exoskeletons for stroke patients. Now, their robots can do eyelash extensions

fortune.com·Sep 9, 2026·Amanda Gerut here, pinch hitting for Allie. I was born into a family of sparse eyelashes. Some people have thick, natural doe eyes; for others it’s Maybelline...
LLY neutral

LLY Looks 23.0% Undervalued on GF Value™ Amid Strategic Merida Biosciences Acquisition

gurufocus.com·Aug 31, 2026·On August 31, 2026, Eli Lilly and Co (NYSE: LLY) announced its intent to acquire Merida Biosciences for up to $2.875 billion, a move that underscores Lilly’s ...
LLY bullish

LLY Looks 22.7% Undervalued on GF Value™ After Mounjaro's Cardiovascular Approval

gurufocus.com·Aug 28, 2026·On August 28, 2026, Eli Lilly and Co (NYSE: LLY) announced FDA approval for an expanded indication of its GLP-1 drug, Mounjaro (tirzepatide), to reduce the risk...
LLY neutral

Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus

finance.yahoo.com·Aug 26, 2026·The VanEck Pharmaceutical ETF offers a more concentrated approach with only 26 holdings, focused exclusively on the healthcare sector. Top holdings include Eli ...
LLY bearish

LLY Looks 18.8% Undervalued on GF Value™

gurufocus.com·Aug 26, 2026·On August 26, 2026, Eli Lilly and Co (NYSE: LLY) announced compelling study results showing that prolonged use of its weight loss drug Zepbound significantly re...
LLY neutral

LLY Looks 18.8% Undervalued on GF Value™ as Cost-Saving Study Boosts Outlook

gurufocus.com·Aug 26, 2026·On August 26, 2026, Eli Lilly and Co (NYSE: LLY) announced compelling results from a study demonstrating that its weight management drug Zepbound significantly ...
LLY neutral

Philip Morris International (PM) vs. Altria Group (MO): Which Tobacco Dividend Fits Your Portfolio

insidermonkey.com·Aug 19, 2026·Philip Morris International Inc. (NYSE:PM) and Altria Group, Inc. (NYSE:MO) often come up in the same conversation when investors look for tobacco dividend stoc...
LLY bullish

InduPro raises $77M, begins first human trial of cancer drug

geekwire.com·Aug 14, 2026·Chronicling the Seattle and Pacific Northwest startup scene. SEE MORE InduPro’s ARRIS platform is designed to bring two proteins on the surface of a cell tog...
LLY bullish

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

manilatimes.net·Aug 13, 2026·Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. ...
LLY neutral

Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026

manilatimes.net·Aug 7, 2026·Tokyo, Japan and Cambridge, UK, 7August 2026 - Nxera Pharma ("the Company” or "Nxera”; TSE: 4565) provides an update on operational activities and reports i...
LLY neutral

Eli Lilly: Fine Q2 2026 Results, But Alertness Required (NYSE:LLY)

seekingalpha.com·Aug 6, 2026·Eli Lilly and Company ( LLY ) gained 4.7% yesterday following the pre-market release of its Q2 2026 results , marking the biggest single session gains since I l...
LLY bullish

Pfizer Inc. (PFE) vs. Eli Lilly and Company (LLY): The Growth vs. Value Play in Pharma

insidermonkey.com·Jul 30, 2026·Pfizer (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) offer unique divergent investment opportunities in the pharmaceutical industry. While one acts as a value...
LLY bullish

Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight

manilatimes.net·Jul 28, 2026·The amylin analogs and combination therapies competitive landscape report delivers important insights into approved as well as ongoing research of 20+ pipeline ...
LLY neutral

Questex’s Fierce Pharma Unveils Fierce Pharma Week’s 2026 Conference Program, Explores What’s Next in the Pharmaceutical Industry

manilatimes.net·Jul 28, 2026·Health Advocate Tamsen Fadal will Deliver Keynote Offering Fresh Perspectives on Leadership, Resilience, Innovation and the Power of Storytelling Fierce Pharma...
LLY neutral

Claris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership Appointments

manilatimes.net·Jul 28, 2026·Positive proof-of-concept clinical data show substantial improvements in visual acuity in limbal stem cell deficiency (LSCD) patients treated with CSB-001 Pivo...
LLY bearish

PJP vs. IYH: Which Healthcare ETF Is the Better Buy?

finance.yahoo.com·Jul 20, 2026·The iShares U.S. Healthcare ETF (NYSEMKT:IYH) provides broad exposure to the medical sector at a lower cost, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP)...
LLY neutral

IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?

finance.yahoo.com·Jul 19, 2026·Investors comparing the iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) and the iShares Global Healthcare ETF (NYSEMKT:IXJ) must choose between concentrated U.S....
LLY neutral

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 - The Stock Now Trades Above $1,200

manilatimes.net·Jul 17, 2026·NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Atlas Healthcare Fund managed by VST Capital , today highlighted a series of early conviction investment decisions t...
LLY neutral

AdvanCell Closes $315 Million Series D

vcnewsdaily.com·Jul 16, 2026·AdvanCell Closes $315 Million Series D Back to Home BOSTON, MA, AdvanCell, a clinical-stage radiopharmaceutical company, announced the closing of an oversubscr...
LLY neutral

Tuberculosis Clinical Trial Pipeline Shows Potential with Active Contributions from 28+ Key Companies | DelveInsight

manilatimes.net·Jul 14, 2026·The tuberculosis clinical trial analysis report delivers important insights into ongoing research of 30+ pipeline tuberculosis drugs, clinical strategies, upcom...
LLY bullish

Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands

investorideas.com·Jul 10, 2026·Biotech · Markets Commentary NYSE: LLY JPMorgan lifted Eli Lilly to $1,400 and AbbVie drew a string of target hikes as a new Medicare GLP-1 program widens acc...
LLY neutral

Flare Therapeutics Secures $85M Series C Round

vcnewsdaily.com·Jul 10, 2026·Flare Therapeutics Secures $85M Series C Round Back to Home CAMBRIDGE, MA, Flare Therapeutics, a clinical-stage biotechnology company, announced the closing of...
LLY neutral

Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

finance.yahoo.com·Jul 9, 2026·Quick Read OZEM holds Lilly at 16% and Novo Nordisk at 13%, concentrating nearly 30% in GLP-1 leaders versus XLV's diluted multi-sector exposure. OZEM rounds ...
LLY bearish

Inside THNR: A Leaner Approach to Weight Loss Investing

etftrends.com·Jul 7, 2026·Demand for GLP-1 weight loss drugs has reshaped the healthcare industry. And ETFs such as the Amplify Weight Loss Drug & Treatment ETF (THNR) give investors a w...
LLY bearish

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?

finance.yahoo.com·Jul 7, 2026·Viking Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for metabolic and endocrine disorders. Its primary focus is on obesity...
LLY bullish

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

finance.yahoo.com·Jul 6, 2026·Can high-flying growth justify a premium valuation, or is a recovered value play the safer bet for 2026? Investors are weighing Eli Lilly and (NYSE:LLY) against...
LLY bullish

Eli Lilly and Company (LLY) Fell on Regulatory And Pricing Policy Challenges

insidermonkey.com·Jul 6, 2026·When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward...
LLY neutral

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

zacks.com·Jul 6, 2026·We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All...
LLY neutral

Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?

finance.yahoo.com·Jul 6, 2026·The short, but glib, answer to the headline question posed for Viking Therapeutics (NASDAQ: VKTX) investors is "no," because the likelihood is that the $4.6 bil...
LLY bearish

IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?

finance.yahoo.com·Jul 5, 2026·The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers lower fees and a higher dividend yield, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) spreads it...
LLY bullish

Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly

finance.yahoo.com·Jul 4, 2026·Quick Read Mounjaro and Zepbound drove Lilly's revenue up 56% while JNJ grew 10% and extended its dividend streak to 64 consecutive years. Lilly partnered wit...